UCSF's Prusiner receives President's National Medal of Science

October 15, 2010

UCSF Nobel laureate Stanley B. Prusiner, MD, UCSF professor of neurology and director of the Institute for Neurodegenerative Diseases, today (Oct. 15, 2010) was named to receive the National Medal of Science, the nation's highest honor for science and technology.

Prusiner was among 10 recipients named by President Barack Obama. In addition, three individuals and one team were named as recipients of the National Medal of Technology and Innovation. All of the awardees will receive their medals at a White House ceremony later this year.

The National Medal of Science honors individuals in a variety of fields for pioneering scientific research that has led to a better understanding of the world, as well as to the innovations and technologies that give the United States its global economic edge. It is administered by the National Science Foundation, established by Congress in 1959.

Prusiner received the medal for his discovery of and ongoing research on a novel infectious agent, which he named the prion (PREE-on). The prion, composed solely of protein, causes bovine spongiform encephalopathy, or "mad cow" disease, and other related fatal neurodegenerative diseases in animals and humans. Prusiner and colleagues are working on better methods for detecting prions and on the development of effective treatments for prion diseases.

In 1997, Prusiner won the Nobel Prize in Physiology or Medicine for his discovery.

In recent years, Prusiner has intensified his focus on developing preventions and cures for the neurodegenerative diseases that include the prion diseases as well as the more common disorders, Alzheimer's and Parkinson's diseases, at the Institute for Neurodegenerative Diseases (IND), involving faculty at six University of California campuses. He considers Alzheimer's disease one of the most devastating and underfunded illnesses affecting society, and is advocating strongly for a substantial increase in federal funding for research.

"Alzheimer's disease afflicts 5.3 million people in America," said Prusiner. "Each year, about 500,000 people die with cancer and about the same number die with Alzheimer's. Yet, Alzheimer's research receives only $450 million annually from the National Institutes of Health, about 1/15th that devoted to cancer research. We urgently need to increase funding to make substantial breakthroughs."

Pioneering Prion Research Noting Prusiner's "vision, perseverance and courage in the face of skeptics as he pioneered prion research two decades ago," UCSF Chancellor Susan Desmond-Hellman, MD, MPH, called him an "inspiration to us all."

"His revelations regarding prions have dramatically impacted scientists' understanding not only of prion diseases, but also of the more common neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis," she said. "He represents the best in translational science - driving basic research toward therapies for patients."

Prusiner's discovery that a protein alone could be infectious was considered heretical when he reported it in 1982. At the time, scientists believed that infections could only be transmitted by bacteria, viruses, fungi and parasites, all which have genomes composed of either DNA or RNA. Protein is composed of amino acids.

Prusiner determined that a normal form of prion protein exists in all mammals, including humans, and that the protein becomes lethal when it acquires an aberrant shape in brain cells. He showed that a particular segment of the normal prion protein loses its corkscrew-shape structure (known as an alpha helix) and flattens into so-called beta sheets. Once it does, the beta sheet form latches on to a neighboring prion protein, twisting its normal spiral tendrils flat. This activity occurs throughout the brain in a domino effect. The damaged proteins ultimately cause death of nerve cells in the brain.

His research has informed scientists' understanding that all neurodegenerative diseases - including Alzheimer's disease, frontotemporal dementias, Parkinson's disease, amyotrophic lateral sclerosis and Huntington's disease - involve the accumulation of proteins that have lost their normal shape. Each disease is caused by a different protein, but research on the abnormal prion protein has fueled scientists' understanding of a prion-like phenomenon in each of the diseases.

"The work of Dr. Prusiner has led to more knowledge about prion diseases than any other form of neurodegeneration," said Jeffrey Bluestone, PhD, UCSF executive vice chancellor and provost. "But, as importantly, these discoveries have forged a new understanding of neurodegenerative disease processes that will lead to new treatments for devastating diseases such as Alzheimer's and Parkinson's."

The awarding of the National Medal of Science "is a fitting recognition of Dr. Prusiner's visionary work, and a great honor for UCSF," said Sam Hawgood, MBBS, dean of the School of Medicine and vice chancellor of medical affairs. "He exemplifies UCSF's commitment to excel in biomedical research and bring discoveries to patients."

Advancing Neurosciences Research Today, at age 68, Prusiner is a key force behind UCSF's development of a neuroscience building that will gather under one roof clinicians, clinician-researchers and basic scientists to accelerate advances against such disorders as Alzheimer's disease, Parkinson's disease, multiple sclerosis, stroke, migraine, epilepsy, autism, mental retardation and cerebral palsy. The building is a milestone in the evolution of UCSF's world-class neuroscience enterprise.

"This culminates a 10-year dream," said Prusiner. "This building will bring together some of the best scientists in the world to work on these common diseases of the brain. The opportunity for major progress is tremendous."

The research space provided by the neuroscience building and the space in the adjacent Arthur and Toni Rembe Rock Hall neuroscience building at UCSF Mission Bay will together constitute "more than 400,000 square feet dedicated to studying these extremely complex, challenging diseases," Prusiner said. "UCSF Mission Bay will be one of the biggest neuroscience complexes in the world."

The need for such intensive focus is crucial, he said. "The last three decades have seen unprecedented advances in our understanding of the molecular, genetic and cellular basis of neurodegenerative diseases. We have a fundamental understanding of the proteins underlying such devastating illnesses as Alzheimer's disease, Parkinson's disease, frontotemporal dementias, ALS and prion diseases, and are moving in on the development of targeted drug therapies.

"But we have strides yet to make. No effective treatments have been introduced for any neurodegenerative disease since L-dopa was introduced for Parkinson's disease in 1967. And even that drug, while effective in treating symptoms until the brain becomes resistant, does not stop the progression of the underlying neurodegeneration."

Prusiner is the fourth UCSF scientist to be awarded the National Medal of Science. Herbert Boyer, PhD, professor emeritus of biochemistry, received the award in 1990 for co-co-pioneering the development of recombinant DNA technology, and pioneering the use of the technology to create medically useful drugs. The seminal breakthrough led to the birth of biotechnology.

J. Michael Bishop, MD, a chancellor emeritus of UCSF and professor of microbiology and immunology, received the award in 2003 for his co-discovery of proto-oncogenes--normal genes that can be converted to cancer genes by genetic damage. Harold Varmus, MD, who shared the Nobel Prize in Physiology or Medicine with Bishop in 1989, received the medal in 2001. Their work eventually led to the recognition that all cancer probably arises from damage to normal genes, and provided new strategies for the detection and treatment of cancer.

Along with Prusiner, one other University of California scientist was named today as 2010 National Medal of Science laureate: Marye Anne Fox, of the University of California, San Diego.
-end-
UCSF is a leading university dedicated to promoting health worldwide through advanced biomedical research, graduate-level education in the life sciences and health professions, and excellence in patient care.

Related links:

White House news release on 2010 National Medal of Science and National Medal of Technology and Innovation http://www.whitehouse.gov/the-press-office/2010/10/15/president-obama-honors-nations-top-scientists-and-innovators

UCSF Neuroscience Building to drive advances against brain diseases http://news.ucsf.edu/releases/ucsf-neuroscience-building-to-drive-advances-against-brain-diseases/

Institute for Neurodegenerative Diseases http://ind.ucsf.edu/ind/

Science magazine
Could They All Be Prion Diseases? Recent studies have renewed interest in the idea that many neurodegenerative diseases may involve prionlike mechanisms. http://www.sciencemag.org/cgi/content/full/326/5958/1337

Follow UCSF on Twitter twitter.com/ucsf

University of California - San Francisco

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.